This article is more than 5 years old. Information may no longer be current.
Loss of color vision, VA possible with cancer drug
Click Here to Manage Email Alerts
WASHINGTON — Patients with persistent or recurrent cutaneous T-cell lymphoma who have been prescribed denileukin diftitox may experience loss of visual acuity with a loss of color vision, according to the manufacturer.
Ligand Pharmaceuticals notified health care providers that patients using Ontak (denileukin diftitox) might experience an adverse reaction after administration. The company has updated the warnings on its packaging and in its prescribing information to indicate the potential reaction.
Specifically, Ligand said in a press release that “loss of visual acuity usually with loss of color vision with or without retinal pigment mottling has been reported following administration of Ontak. Recovery was reported in some of the affected patients; however, most patients reported persistent visual impairment.”